SCHEMBL1035290

SCHEMBL1035290

O=C(Nc1cccnc1)Nc1cccc2ccc(-c3cccc(OC(F)(F)F)c3)nc12

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 1/20 0.55
RAB9A P51151 1/20 0.55
KDR P35968 4/20 0.54
EGFR P00533 2/20 0.49
FGFR1 P11362 2/20 0.49
DYRK1A Q13627 1/20 0.47
ABL1 P00519 3/20 0.46
OPRM1 P35372 1/20 0.46
KCNH2 Q12809 1/20 0.46
MAPT P10636 2/20 0.45
SIRT2 Q8IXJ6 1/20 0.45
KDM4E B2RXH2 1/20 0.44
HSD17B10 Q99714 1/20 0.44
TRPV1 Q8NER1 2/20 0.44
TAAR1 Q96RJ0 1/20 0.43
AHR P35869 1/20 0.43
FYN P06241 1/20 0.43
CYP11B1 P15538 1/20 0.43
CYP11B2 P19099 1/20 0.43
MEN1 O00255 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1030617 0.86 ABL1 (0.52) NPC1RAB9ADYRK1AABL1OPRM1
SCHEMBL1034313 0.83 SLC40A1 (0.49) NPC1RAB9AKDRDYRK1AABL1
SCHEMBL1035542 0.82 EGFR (0.52) NPC1RAB9AKDREGFRFGFR1
SCHEMBL1029914 0.81 NPC1 (0.52) NPC1RAB9ADYRK1AABL1OPRM1
SCHEMBL1029917 0.81 EGFR (0.54) NPC1RAB9AKDREGFRFGFR1
SCHEMBL1029916 0.79 HDAC1 (0.52) KDRDYRK1AABL1SIRT2
SCHEMBL1032557 0.78 CYP3A4 (0.55) DYRK1AKDM4EHSD17B10CYP11B1CYP11B2
SCHEMBL1076614 0.77 HDAC1 (0.51) NPC1RAB9AEGFRABL1KDM4E
SCHEMBL13187196 0.77 ABL1 (0.48) NPC1RAB9AABL1OPRM1KCNH2
SCHEMBL1035313 0.76 IRAK4 (0.47) NPC1RAB9AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2273992-B1 QUINOLINES AND RELATED ANALOGS AS SIRTUIN MODULATORS GLAXOSMITHKLINE LLC (US) 2016-05-25 EP disclosed
EP-2273992-B1 QUINOLINES AND RELATED ANALOGS AS SIRTUIN MODULATORS GLAXOSMITHKLINE LLC (US) 2016-05-25 EP disclosed
US-20110046110-A1 QUINOLINES AND RELATED ANALOGS AS SIRTUIN MODULATORS GLAXOSMITHKLINE LLC 2011-02-24 US disclosed
US-20110046110-A1 QUINOLINES AND RELATED ANALOGS AS SIRTUIN MODULATORS GLAXOSMITHKLINE LLC 2011-02-24 US disclosed
US-20110046110-A1 QUINOLINES AND RELATED ANALOGS AS SIRTUIN MODULATORS GLAXOSMITHKLINE LLC 2011-02-24 US disclosed
EP-2273992-A1 QUENOLINES AND RELATED ANALOGS AS SIRTUIN MODULATORS Sirtris Pharmaceuticals, Inc. (US) 2011-01-19 EP disclosed
WO-2009134973-A1 QUENOLINES AND RELATED ANALOGS AS SIRTUIN MODULATORS SIRTRIS PHARMACEUTICALS, INC. (US) 2009-11-05 WO disclosed
WO-2009134973-A1 QUENOLINES AND RELATED ANALOGS AS SIRTUIN MODULATORS SIRTRIS PHARMACEUTICALS, INC. (US) 2009-11-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110046110-A1 QUINOLINES AND RELATED ANALOGS AS SIRTUIN MODULATORS SIRT3, SIRT1, SIRT2 NPC1 3386/4885RAB9A 660/4885KDR 1845/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.